EarningsQ2 2026 Earnings Report
MX:LABB Q2 2026 EPS Results
Actual EPS$0.37
Consensus EPS$0.47
Beat/MissMissed by -$0.10
One Year Ago EPS$0.35
MX:LABB Q2 2026 Revenue Results
Actual Revenue$4.40B
Expected Revenue$4.49B
Beat/MissMissed by -$88.16M
YoY Revenue Growth-5.97%
Earnings Announcement Details
QuarterQ2 2026
Date07/23/2026
TimeBefore Open
Conference CallThursday, July 23, 2026
MX:LABB Upcoming Earnings
Genomma Lab Internacional SAB de CV's next earnings date is estimated for October 28, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:LABB Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed cautious optimism: management reported clear signs of recovery in Mexico (improving monitored sellout, narrowing sell-in/sell-out gap, and strong Suerox momentum), structural productivity gains that expanded gross margin, solid regional growth in Latin America, and a conservative balance sheet with liquidity improvements. At the same time, meaningful top-line pressures remain (net sales down 6% and a strong peso translation headwind), the United States market is disrupted, EBITDA margin contracted on operational deleverage, and free cash flow was materially lower due to working capital investments. Overall, management framed the negatives as temporary and deliberate investments to defend and grow market share while expecting gradual recovery in H2 2026 and margin normalization in 2027.Company Guidance
Sequential Recovery in Mexico Sellout
Monitored Mexican sellout improved sequentially from -15.7% in April to -10.0% in May and -6.8% in June (9-point improvement within Q2); monitored sellout turned positive at +2.4% in the first two weeks of July, with the leading retailer going from -7% in April to +4% in May, +5.2% in June and +15.3% in early July (34-point recovery from Q2 2025 low). Sell-in to sell-out gap narrowed to 43 basis points, indicating healthier channel inventories.
Suerox Strong Performance and Margin Expansion
Suerox showed sustained double-digit growth at the leading retailer; share at that retailer climbed to 12.2% in the second week of July (up 3.6 percentage points vs Q1). Suerox Mexico gross margin grew 11.7 percentage points in Q2 (8 points year-over-year) and is 2.8 points above pre-discount levels despite a price cut from MXN 25 to MXN 22 and fully absorbing a MXN 1-per-bottle tax.
Productivity Drove Gross Margin Expansion
Consolidated gross margin expanded 106 basis points to 64.6% in Q2 2026, driven by structural productivity gains that offset higher promotional spend and the new tax impact.
Profitability Maintained and Net Income Growth
EBITDA totaled MXN 959 million with a margin of 21.8% (down 200 basis points YoY on operational deleverage), while net income increased 5.5% to MXN 375 million and net margin expanded 93 basis points to 8.5%, aided by lower financial expenses and reduced FX losses.
Regional Growth Outside Mexico
Latin America ex-Argentina (30% of mix) grew +5.6% driven by Central America and the Andean region; Argentina grew 37.7% (outpacing inflation by 4.5 percentage points). Like-for-like Latin America sales grew 3.9% and regional EBITDA margin improved 41 basis points to 25.1%.
Strong Balance Sheet and Capital Actions
Trailing 12-month free cash flow totaled MXN 1.259 billion. Net debt/EBITDA was a conservative 1.38x and debt service coverage 5.2x. The company paid its 16th consecutive quarterly dividend (MXN 0.20 per share, MXN 200 million total) and secured a MXN 1.5 billion 10-year amortizing term loan after quarter-end to strengthen liquidity and maturity profile.
MX:LABB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed